4
Participants
Start Date
January 4, 2021
Primary Completion Date
December 7, 2022
Study Completion Date
December 7, 2022
Volixibat
Oral capsules, administered twice daily. Volixibat is an ileal bile acid transporter (IBAT) inhibitor.
Placebo
Capsules matched to study drug minus active substance.
Dunedin Hospital, Dunedin
Capital & Coast District Health Board, Wellington Regional Hospital, Wellington
Christchurch Women's Hospital, Christchurch
University of Miami, Miami
University of Alabama at Birmingham, Birmingham
The Ohio State University Wexner Medical Center, Columbus
University of Texas Health Science Center, Houston
The University of Texas Medical Branch - Galveston, Galveston
University of Texas Health Science Center at San Antonio, San Antonio
Yale School of Medicine, New Haven
Medway NHS Foundation Trust, Gillingham
Bradford Royal Infirmary, Bradford
Birmingham Womens and Childrens NHS Foundation Trust, Birmingham
University Hospital of Wales, Cardiff
St Richard's Hospital, Chichester
Barts Health NHS Trust- Whipps Cross University Hospital, London
Royal Free London Hospital NHS Foundation Trust, London
Guy's and St Thomas' NHS Foundation Trust, London
West Middlesex University Hospital, Middlesex
The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne
Lead Sponsor
Mirum Pharmaceuticals, Inc.
INDUSTRY